Development of Novel Biologics that Promote T Cell-Mediated Depletion of Pathogenic Cell Types in Autoimmune Disease
- Introduction to the Immuno-STAT™ platform for selective regulation of antigen-specific T cells
- Lead candidate CUE-501 differentiates from pan-TCEs by selectively engaging existing virus-specific T cells to deplete pathogenic B cells while minimising systemic immune activation and CRS risk
- The modularity of the Immuno-STAT™ platform enables opportunities to target additional pathogenic cell types beyond B cells and opens avenues for novel therapeutic approaches in autoimmunity and oncology